图为深圳 市希格生科（深圳）有限公司创始人兼CEO张海生进行分享。主办方供图 福田的饺子宴已连续23年陪伴来深建设者迎新纳福。今年，团福田区委请来了三位不同领域的青年代 表，分享自己的青春故事。 深圳市希格生科（深圳）有限公司创始人兼CEO张海生分享了选择扎根福田河套，在类器官+AI领域勇 闯无人区成功斩获盖伦奖的经历；"清华包子哥"陶强讲述了从国企经理转型餐饮创业者的故事，他历经 行业起伏仍扎根民生刚需，在福田政策加持下让"青春小店"撑起大梦想，他的包子铺39平方米每个月能 卖到30万元；飞船音乐主理人李帅则把在福田创业、生活的故事融进原创歌曲《福田的歌》中，用音符 勾勒出青年的逐梦图景。 图为活动 中国青年报客户端讯（中青报·中青网记者 刘芳）2月6日晚，位于深圳市福田区广电金融中心48楼的天 空美术馆里，近百位来自福田科创企业、创业公司、新兴领域、志愿服务等领域的青年代表欢聚一堂， 以饺为媒，话团圆、聊奋斗、迎新春。 现场。主办方供图 福田区委副书记、政法委书记曾乐非现场致辞，向奋斗在福田的青年朋友们致以新春问候，他表 示："选择福田，就是选择将个人的才华与梦想，包进一座城区奔腾向前的时代洪流中！" 来 ...

Core Insights - Hige Biotechnology (Shenzhen) Co., Ltd. has completed a Series A financing round of 80 million RMB, led by multiple investors including Jingtai Technology and Songhe Capital [1] - The funds will primarily be used to advance the global Phase II clinical trial of the company's lead pipeline SIGX1094 and the IND application and Phase I clinical trial of the second pipeline SIGX2649, focusing on targeted therapies for metastatic solid tumors [1] - Hige Biotechnology was established in 2020, utilizing an innovative "organoid + AI" drug development platform to address significant unmet clinical needs in cancers such as gastric cancer, liver cancer, and lung cancer [1] Company Pipeline - The company has four first-in-class drug pipelines and an organoid platform, with SIGX1094 being the world's first targeted drug for metastatic gastric cancer, having received clinical trial approvals in both the U.S. and China, along with orphan drug designation and fast track designation from the U.S. [2] - SIGX1094 is currently undergoing Phase I clinical trials at Peking University Cancer Hospital and is the first drug pipeline to reach clinical stages through the "organoid + AI" technology platform [2] - The second pipeline, SIGX2649, is a pan-TEAD inhibitor targeting a key downstream effector of the Hippo signaling pathway, with no marketed drugs currently available for this target, and is set to apply for clinical trials simultaneously in the U.S. and China [2]

Group 1 - The core point of the article is that Xige Biotechnology (Shenzhen) Co., Ltd. has recently completed an A-round financing of 80 million RMB to accelerate the global clinical development of its "organoid + AI" innovative drug pipeline [1] - Xige Biotechnology was established in 2020 and is located in Shenzhen, focusing on research and experimental development [1] - The company has a registered capital of 1.69084205 million RMB and has completed its A-round financing by 2026, with a transaction amount of 80 million RMB [1] Group 2 - The company holds 21 trademark registrations and 13 patents, along with 10 administrative licenses [1] - The shareholders of Xige Biotechnology include Shenzhen Xige New Research Biotechnology Partnership, Zhang Haisheng, Shenzhen Xige Inno Biotechnology Partnership, XtalPi Investment Limited, and Shenzhen Tiantuo Xing Shen Angel Investment Partnership [1]

Group 1 - The 2025 Prix Galien USA nominations were announced, with Signet Therapeutics being the only Chinese biopharmaceutical company nominated for the Best Biotechnology Award for its drug SIGX1094R, a targeted therapy for diffuse gastric cancer [1][2] - SIGX1094R is the world's first drug developed using the "organoid + AI" platform and has received IND approvals from both the FDA and China's National Medical Products Administration, along with orphan drug designation and fast track designation from the FDA [1] - The drug is currently undergoing Phase I clinical trials at Peking University Cancer Hospital and is expected to enter Phase II clinical trials by the end of 2025 [1] Group 2 - Signet Therapeutics is the world's first "organoid + AI" innovative drug development company, recognized as a national high-tech enterprise and a specialized and innovative enterprise [2] - The founding team of the company comes from prestigious institutions such as Harvard University, MIT, and the Chinese Academy of Sciences, with over 20 groundbreaking research papers published in high-impact journals in the field of gastric and esophageal cancer [2] - The company has completed nearly 220 million yuan in financing and project funding, holding over 40 core intellectual properties [2]

Group 1 - The "Shenzhen Venture Capital Day" event aims to accelerate the commercialization of technological achievements in the life and health sector, promoting high-quality development of the industry cluster in Shenzhen and the Greater Bay Area [1][3] - The event featured six innovative life and health technology projects, showcasing advancements from basic research to clinical applications [1][2] - Notable projects included a self-adaptive stereotactic radiotherapy system for breast cancer, a flexible electrode for brain-machine interfaces, and a targeted drug for diffuse gastric cancer that has entered phase I clinical trials [2][3] Group 2 - The event facilitated deep exchanges between over 60 investors and representatives from entrepreneurial service institutions, enhancing the atmosphere for investment and collaboration [2] - The integration of innovation resources at the International Headquarters is expected to foster robust growth in Shenzhen's life and health industry [3] - The event serves as a platform for innovative projects to gain visibility and for investment institutions to discover quality projects, thereby injecting new momentum into the cultivation of new productivity and high-quality economic development in the Greater Bay Area [3]